Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 305

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 305
---
 preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common
stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.

Options

As of , shares of common stock were issuable upon the exercise of
outstanding stock options, at a weighted-average exercise price of $ per share. For additional information regarding terms of our equity incentive plans, see the section titled “Executive Compensation—Equity
Benefit Plans.”

Warrants

Class A Warrants

In
November 2018 and March 2019, we issued warrants to certain investors to purchase an aggregate of 913,873 shares of our common stock at an exercise price per share of $2.30, subject to adjustment as set forth in the warrant, or the Class A
Warrants. In August 2023, in conjunction with the Series C financing, we modified the outstanding Class A Warrants and reduced the exercise price to $0.01. As of December 31, 2024, Class A Warrants to purchase up to 695,961 shares of our
common stock remained unexercised. The Class A Warrants include a cashless exercise feature allowing the holder to receive shares underlying the applicable Class A Warrant in an amount reduced by the aggregate amount of the exercise price
that would have been payable upon exercise of the applicable Class A Warrant for such shares. Each Class A Warrant is exercisable until the 10 anniversary from its issuance date. The
Class A Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to subsequent sales of shares of our common stock at an issuance price per share that is less than the then-effective exercise price of the
Class A Warrants. The warrant holder is not a stockholder and has none of the rights of a stockholder until the warrant is exercised and the shares of common stock are issued upon exercise.

Class B Warrants

In
November 2018 and March 2019, we issued warrants to certain investors to purchase an aggregate of 913,873 shares of our common stock at an exercise price per share of $2.30, subject to adjustment as set forth in the warrant, or the Class B
Warrants. In August 2023, in conjunction with the Series C financing, we modified the outstanding Class B Warrants and reduced the exercise price to $0.01. As of December